DK1713504T3 - Antimicrobial preservatives to obtain multi-dose formulations using beta-cyclodextrins for liquid dosage forms - Google Patents

Antimicrobial preservatives to obtain multi-dose formulations using beta-cyclodextrins for liquid dosage forms Download PDF

Info

Publication number
DK1713504T3
DK1713504T3 DK05702263.4T DK05702263T DK1713504T3 DK 1713504 T3 DK1713504 T3 DK 1713504T3 DK 05702263 T DK05702263 T DK 05702263T DK 1713504 T3 DK1713504 T3 DK 1713504T3
Authority
DK
Denmark
Prior art keywords
compound
cyclodextrin
formula
cresol
meta
Prior art date
Application number
DK05702263.4T
Other languages
Danish (da)
English (en)
Inventor
Roger Christopher Adami
Frederick Pfizer Global R & D David
Julia Ann Wood
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1713504(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Application granted granted Critical
Publication of DK1713504T3 publication Critical patent/DK1713504T3/en

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
DK05702263.4T 2004-01-30 2005-01-17 Antimicrobial preservatives to obtain multi-dose formulations using beta-cyclodextrins for liquid dosage forms DK1713504T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54089704P 2004-01-30 2004-01-30
PCT/IB2005/000100 WO2005082416A2 (en) 2004-01-30 2005-01-17 Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms

Publications (1)

Publication Number Publication Date
DK1713504T3 true DK1713504T3 (en) 2017-08-07

Family

ID=34910697

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05702263.4T DK1713504T3 (en) 2004-01-30 2005-01-17 Antimicrobial preservatives to obtain multi-dose formulations using beta-cyclodextrins for liquid dosage forms

Country Status (25)

Country Link
US (1) US8183230B2 (https=)
EP (1) EP1713504B1 (https=)
JP (1) JP5021318B2 (https=)
KR (1) KR100834232B1 (https=)
CN (1) CN101090735A (https=)
AR (2) AR047469A1 (https=)
AU (1) AU2005216709B2 (https=)
BR (1) BRPI0506496B8 (https=)
CA (1) CA2554346C (https=)
CO (1) CO5700794A2 (https=)
CY (1) CY1119188T1 (https=)
DK (1) DK1713504T3 (https=)
ES (1) ES2638113T3 (https=)
HU (1) HUE034099T2 (https=)
IL (1) IL176676A0 (https=)
LT (1) LT1713504T (https=)
NO (1) NO20063858L (https=)
NZ (1) NZ548236A (https=)
PL (1) PL1713504T3 (https=)
PT (1) PT1713504T (https=)
RU (1) RU2332997C2 (https=)
SI (1) SI1713504T1 (https=)
TW (1) TW200524632A (https=)
WO (1) WO2005082416A2 (https=)
ZA (1) ZA200605148B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201401597TA (en) 2011-11-29 2014-05-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
HUE054186T2 (hu) * 2013-07-19 2021-08-30 Boehringer Ingelheim Vetmedica Gmbh Éterezett ciklodextrin-származékokat tartalmazó, tartósított, folyékony, vizes gyógyászati készítmény
ES2883448T3 (es) 2013-12-04 2021-12-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmacéuticas mejoradas de pimobendán
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CA3104811C (en) 2017-06-30 2024-05-28 Chase Therapeutics Corporation Composition comprising pramipexole and nk1-antagonists for treating depression
EP3923916A4 (en) * 2019-02-15 2022-12-21 Saol International Development Ltd. INJECTABLE PHENOL FORMULATIONS AND METHODS OF USE
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法
AT527172A1 (de) 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910510A (ja) * 1982-07-08 1984-01-20 Nippon Zenyaku Kogyo Kk 低刺激性チアムリン注射剤
JPS59152320A (ja) * 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
JPS6419737A (en) * 1987-07-15 1989-01-23 Hitachi Ltd Multilayer interconnection tape carrier
JPH039848A (ja) * 1989-06-06 1991-01-17 Canon Inc 液体噴射記録装置
UA27776C2 (uk) * 1991-05-31 2000-10-16 Пфайзер Інк. Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
DK0668863T3 (da) * 1992-11-12 1997-06-30 Pfizer Quinuclidinderivat som substans P-antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
AU5975700A (en) 1999-07-02 2001-01-22 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1383445A4 (en) * 2001-03-20 2005-04-13 Cydex Inc FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN
SK252004A3 (sk) * 2001-07-20 2005-03-04 Pfizer Products Inc. Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov
BR0307898A (pt) 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
BRPI0507301A (pt) 2004-01-30 2007-06-26 Pfizer Prod Inc composições farmacêuticas de antagonistas do receptor de nuerocinina e ciclodextrina e métodos para melhor toleráncia no local de injeção
MXPA06007964A (es) 2004-01-30 2007-01-26 Pfizer Prod Inc Antagonistas del receptor nk-1 para mejorar la recuperacion de anestesia.
KR100812046B1 (ko) 2004-02-02 2008-03-10 화이자 프로덕츠 인크. 1-(2s,3s)-2-벤즈히드릴-n-(5-삼급-부틸-2-메톡시벤질)퀴누클리딘-3-아민의 제조 방법

Also Published As

Publication number Publication date
EP1713504A2 (en) 2006-10-25
WO2005082416A3 (en) 2006-07-27
AR047469A1 (es) 2006-01-18
AU2005216709A1 (en) 2005-09-09
AR109357A2 (es) 2018-11-21
PT1713504T (pt) 2017-08-29
US20070155697A1 (en) 2007-07-05
ZA200605148B (en) 2007-10-31
CO5700794A2 (es) 2006-11-30
WO2005082416A2 (en) 2005-09-09
LT1713504T (lt) 2017-09-11
RU2006127422A (ru) 2008-03-10
NO20063858L (no) 2006-10-19
KR100834232B1 (ko) 2008-05-30
RU2332997C2 (ru) 2008-09-10
JP2007519703A (ja) 2007-07-19
CY1119188T1 (el) 2018-02-14
SI1713504T1 (sl) 2017-10-30
CN101090735A (zh) 2007-12-19
NZ548236A (en) 2010-02-26
JP5021318B2 (ja) 2012-09-05
ES2638113T3 (es) 2017-10-18
IL176676A0 (en) 2006-10-31
US8183230B2 (en) 2012-05-22
BRPI0506496A (pt) 2007-02-13
KR20060128973A (ko) 2006-12-14
HUE034099T2 (en) 2018-01-29
BRPI0506496B1 (pt) 2018-10-09
TW200524632A (en) 2005-08-01
CA2554346C (en) 2009-11-17
CA2554346A1 (en) 2005-09-09
EP1713504B1 (en) 2017-06-07
BRPI0506496B8 (pt) 2022-09-20
PL1713504T3 (pl) 2017-12-29
BRPI0506496A8 (pt) 2017-11-14
AU2005216709B2 (en) 2008-02-07

Similar Documents

Publication Publication Date Title
US20240307368A1 (en) Antimicrobial compositions
US7034013B2 (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CA2441744C (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
DK1713504T3 (en) Antimicrobial preservatives to obtain multi-dose formulations using beta-cyclodextrins for liquid dosage forms
CN113181110A (zh) 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
US20070129328A1 (en) Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
MXPA06008032A (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
HK1115057A (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
HK1196530B (en) Antimicrobial compositions